CNS PharmaceuticalsCNSP
13F holders, Q4 2025 (December 31)9holders +1
3new positions
2sold out
$5.25avg. 13F price*
At the end of Q4 2025, 9 institutions reported holding CNS Pharmaceuticals Inc. (CNSP) in their 13F filings, up 1 from Q3 2025. 3 opened new positions and 2 sold out. The largest holders were Stonepine Capital Management, LLC ($256K), Ikarian Capital, LLC ($241K) and DRW Securities, LLC ($81K).
- Company
- CNS Pharmaceuticals Inc.
- CUSIP
- 18978H508
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $568K |
| Exits | 2 | $270 |
All 13F filers, Q3 2025 → Q4 2025: 109,560 shares bought and 9,939 shares sold, net +99,621 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Stonepine Capital Management, LLC | 0.20% | New | 48,827 | $256K |
| Ikarian Capital, LLC | 0.03% | New | 45,830 | $241K |
| DRW Securities, LLC | 0.01% | Add +9.8% | 15,429 | $81K |
| Boothbay Fund Management, LLC | 0.00% | New | 13,524 | $71K |
| UBS Group AG | 0.00% | Reduce -94.2% | 611 | $3K |
| Barrett & Company, Inc. | 0.00% | No change | 8 | $42 |
| Bank of America Corp. | 0.00% | No change | 4 | $21 |
| MAI Capital Management | 0.00% | No change | 3 | $16 |
| Danske Bank A/S | 0.00% | No change | 1 | $5 |
"% of holder's portfolio" is CNSP's weight in each manager's 13F, not the share of CNS Pharmaceuticals Inc. the manager owns.